A Study Comparing the Hypnotic Efficacies and Residual Effects on Actual Driving Performance of Midazolam 15 mg, Triazolam 0.5 mg, Temazepam 20 mg and Placebo in Shiftworkers on Night Duty
Riedel, W. J., Quasten, R., Hausen, C., & O'Hanlon, J. F. (1988). A Study Comparing the Hypnotic Efficacies and Residual Effects on Actual Driving Performance of Midazolam 15 mg, Triazolam 0.5 mg, Temazepam 20 mg and Placebo in Shiftworkers on Night Duty (Report No. DOT-HS-EPX-018). Rijksuniversiteit Limburg. Institute for Drugs, Safety and Behavior. https://doi.org/10.21949/1524989
Riedel, W. J., R. Quasten, C. Hausen, and J. F. O'Hanlon. A Study Comparing the Hypnotic Efficacies and Residual Effects on Actual Driving Performance of Midazolam 15 mg, Triazolam 0.5 mg, Temazepam 20 mg and Placebo in Shiftworkers on Night Duty. Report no. DOT-HS-EPX-018. Rijksuniversiteit Limburg. Institute for Drugs, Safety and Behavior, 1988. https://doi.org/10.21949/1524989.
Riedel, W. J., et al. A Study Comparing the Hypnotic Efficacies and Residual Effects on Actual Driving Performance of Midazolam 15 mg, Triazolam 0.5 mg, Temazepam 20 mg and Placebo in Shiftworkers on Night Duty. Rijksuniversiteit Limburg. Institute for Drugs, Safety and Behavior, 1988, Report no. DOT-HS-EPX-018, ROSA P. https://doi.org/10.21949/1524989.
The purpose of the study was to determine the hypnotic efficacy and residual effects of three hypnotics administered for the treatment of transient insomnia in the day-sleep of rotating shift workers. The average duration of day-sleep in rotating shift workers is 5 to 6 hours. Midazolam, triazolam and temazepam all possess short elimination half-lives, i.e. 2, 4 and 8 hours, respectively. This suggests that these drugs should be largely free from residual effects and therefore not impair performance in real-life tasks. It was concluded that midazolam 15 mg can be recommended for use by rotating shift workers in order to cope with transient insomnia caused by poor adaptation to night-shift, and that in general no residual effects will be present 6.5 hours after ingestion. Temazepam 20 mg is less likely to improve day-sleep, but is absolutely free from residual sedative effects. Triazolam 0.5 mg can not be recommended because it is less likely to improve day-sleep and is unsafe to drive with 6.5-8.5 firs after ingestion.
Riedel, W. J., Quasten, R., Hausen, C., & O'Hanlon, J. F. (1988). A Study Comparing the Hypnotic Efficacies and Residual Effects on Actual Driving Performance of Midazolam 15 mg, Triazolam 0.5 mg, Temazepam 20 mg and Placebo in Shiftworkers on Night Duty (Report No. DOT-HS-EPX-018). Rijksuniversiteit Limburg. Institute for Drugs, Safety and Behavior. https://doi.org/10.21949/1524989
Riedel, W. J., R. Quasten, C. Hausen, and J. F. O'Hanlon. A Study Comparing the Hypnotic Efficacies and Residual Effects on Actual Driving Performance of Midazolam 15 mg, Triazolam 0.5 mg, Temazepam 20 mg and Placebo in Shiftworkers on Night Duty. Report no. DOT-HS-EPX-018. Rijksuniversiteit Limburg. Institute for Drugs, Safety and Behavior, 1988. https://doi.org/10.21949/1524989.
Riedel, W. J., et al. A Study Comparing the Hypnotic Efficacies and Residual Effects on Actual Driving Performance of Midazolam 15 mg, Triazolam 0.5 mg, Temazepam 20 mg and Placebo in Shiftworkers on Night Duty. Rijksuniversiteit Limburg. Institute for Drugs, Safety and Behavior, 1988, Report no. DOT-HS-EPX-018, ROSA P. https://doi.org/10.21949/1524989.
ROSA P serves as an archival repository of USDOT-published products including scientific
findings, journal articles, guidelines, recommendations, or other information authored or co-authored by
USDOT or funded partners. As a repository, ROSA P retains documents in their original published format to
ensure public access to scientific information.
Links with this icon indicate that you are leaving a Bureau of Transportation
Statistics (BTS)/National Transportation Library (NTL)
Web-based service.
Thank you for visiting.
You are about to access a non-government link outside of
the U.S. Department of Transportation's National
Transportation Library.
Please note: While links to Web sites outside of DOT are
offered for your convenience, when you exit DOT Web sites,
Federal privacy policy and Section 508 of the Rehabilitation
Act (accessibility requirements) no longer apply. In
addition, DOT does not attest to the accuracy, relevance,
timeliness or completeness of information provided by linked
sites. Linking to a Web site does not constitute an
endorsement by DOT of the sponsors of the site or the
products presented on the site. For more information, please
view DOT's Web site linking policy.
To get back to the page you were previously viewing, click
your Cancel button.